Rofecoxib: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Rofecoxib''' is a [[cyclooxygenase 2 inhibitors|cyclooxygenase 2 inhibitor]] drug used as an analgesic until it was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.<ref>{{cite web |url=http://www.fda.gov/bbs/topics/news/2004/NEW01122.html |title=FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product |accessdate=2007-11-18 |format= |work=|year=2004}}</ref> This was in part due to concerns<ref name="pmid16339408">{{cite journal |author=Curfman GD, Morrissey S, Drazen JM |title=Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8 |journal=N. Engl. J. Med. |volume=353 |issue=26 |pages=2813–4 |year=2005 |month=December |pmid=16339408 |doi=10.1056/NEJMe058314 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16339408&promo=ONFLNS19 |issn=}}</ref> about suppression of negative results due to [[rofecoxib]] in the VIGOR [[randomized controlled trial]]<ref name="pmid11087881">{{cite journal |author=Bombardier C, Laine L, Reicin A, ''et al'' |title=Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group |journal=N. Engl. J. Med. |volume=343 |issue=21 |pages=1520–8, 2 p following 1528 |year=2000 |month=November |pmid=11087881 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11087881&promo=ONFLNS19 |issn=}}</ref>. | '''Rofecoxib''' is a [[cyclooxygenase 2 inhibitors|cyclooxygenase 2 inhibitor]] drug used as an analgesic until it was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.<ref>{{cite web |url=http://www.fda.gov/bbs/topics/news/2004/NEW01122.html |title=FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product |accessdate=2007-11-18 |format= |work=|year=2004}}</ref> This was in part due to concerns<ref name="pmid16339408">{{cite journal |author=Curfman GD, Morrissey S, Drazen JM |title=Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8 |journal=N. Engl. J. Med. |volume=353 |issue=26 |pages=2813–4 |year=2005 |month=December |pmid=16339408 |doi=10.1056/NEJMe058314 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16339408&promo=ONFLNS19 |issn=}}</ref> about suppression of negative results due to [[rofecoxib]] in the VIGOR [[randomized controlled trial]]<ref name="pmid11087881">{{cite journal |author=Bombardier C, Laine L, Reicin A, ''et al'' |title=Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group |journal=N. Engl. J. Med. |volume=343 |issue=21 |pages=1520–8, 2 p following 1528 |year=2000 |month=November |pmid=11087881 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11087881&promo=ONFLNS19 |issn=}}</ref>. | ||
The association was first reported in the original report of the VIGOR trial in 2000<ref name="pmid11087881"/>, and was also reported in a systematic review of published and unpublished studies in 2001<ref name="pmid11509060">{{cite journal| author=Mukherjee D, Nissen SE, Topol EJ| title=Risk of cardiovascular events associated with selective COX-2 inhibitors. | journal=JAMA | year= 2001 Aug 22-29 | volume= 286 | issue= 8 | pages= 954-9 | pmid=11509060 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=11509060 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=11874278 Review in: ACP J Club. 2002 Mar-Apr;136(2):53] </ref>. | |||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 06:00, 13 October 2024
Rofecoxib is a cyclooxygenase 2 inhibitor drug used as an analgesic until it was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.[1] This was in part due to concerns[2] about suppression of negative results due to rofecoxib in the VIGOR randomized controlled trial[3].
The association was first reported in the original report of the VIGOR trial in 2000[3], and was also reported in a systematic review of published and unpublished studies in 2001[4].
References
- ↑ FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product (2004). Retrieved on 2007-11-18.
- ↑ Curfman GD, Morrissey S, Drazen JM (December 2005). "Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8". N. Engl. J. Med. 353 (26): 2813–4. DOI:10.1056/NEJMe058314. PMID 16339408. Research Blogging.
- ↑ 3.0 3.1 Bombardier C, Laine L, Reicin A, et al (November 2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group". N. Engl. J. Med. 343 (21): 1520–8, 2 p following 1528. PMID 11087881. [e]
- ↑ Mukherjee D, Nissen SE, Topol EJ (2001 Aug 22-29). "Risk of cardiovascular events associated with selective COX-2 inhibitors.". JAMA 286 (8): 954-9. PMID 11509060. Review in: ACP J Club. 2002 Mar-Apr;136(2):53